These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

235 related items for PubMed ID: 24493474

  • 21. Effective treatment of metastatic forms of Epstein-Barr virus-associated nasopharyngeal carcinoma with a novel adenovirus-based adoptive immunotherapy.
    Smith C, Tsang J, Beagley L, Chua D, Lee V, Li V, Moss DJ, Coman W, Chan KH, Nicholls J, Kwong D, Khanna R.
    Cancer Res; 2012 Mar 01; 72(5):1116-25. PubMed ID: 22282657
    [Abstract] [Full Text] [Related]

  • 22. Epstein-Barr Virus (EBV)-derived BARF1 encodes CD4- and CD8-restricted epitopes as targets for T-cell immunotherapy.
    Kalra M, Gerdemann U, Luu JD, Ngo MC, Leen AM, Louis CU, Rooney CM, Gottschalk S.
    Cytotherapy; 2019 Feb 01; 21(2):212-223. PubMed ID: 30396848
    [Abstract] [Full Text] [Related]

  • 23. Quantitative PCR for Epstein-Barr virus DNA and RNA in multiple sclerosis.
    Lindsey JW, Hatfield LM, Crawford MP, Patel S.
    Mult Scler; 2009 Feb 01; 15(2):153-8. PubMed ID: 18845656
    [Abstract] [Full Text] [Related]

  • 24. The role of virus-specific CD4+ T cells in the control of Epstein-Barr virus infection.
    Mautner J, Bornkamm GW.
    Eur J Cell Biol; 2012 Jan 01; 91(1):31-5. PubMed ID: 21458882
    [Abstract] [Full Text] [Related]

  • 25. The association of Epstein-Barr virus infection with CXCR3+ B-cell development in multiple sclerosis: impact of immunotherapies.
    van Langelaar J, Wierenga-Wolf AF, Samijn JPA, Luijks CJM, Siepman TA, van Doorn PA, Bell A, van Zelm MC, Smolders J, van Luijn MM.
    Eur J Immunol; 2021 Mar 01; 51(3):626-633. PubMed ID: 33152118
    [Abstract] [Full Text] [Related]

  • 26. Treatment options for post-transplant lymphoproliferative disorder and other Epstein-Barr virus-associated malignancies.
    Davis JE, Moss DJ.
    Tissue Antigens; 2004 Apr 01; 63(4):285-92. PubMed ID: 15009802
    [Abstract] [Full Text] [Related]

  • 27. Epstein-Barr virus microRNAs reduce immune surveillance by virus-specific CD8+ T cells.
    Albanese M, Tagawa T, Bouvet M, Maliqi L, Lutter D, Hoser J, Hastreiter M, Hayes M, Sugden B, Martin L, Moosmann A, Hammerschmidt W.
    Proc Natl Acad Sci U S A; 2016 Oct 18; 113(42):E6467-E6475. PubMed ID: 27698133
    [Abstract] [Full Text] [Related]

  • 28. Transcriptional profile and Epstein-Barr virus infection status of laser-cut immune infiltrates from the brain of patients with progressive multiple sclerosis.
    Veroni C, Serafini B, Rosicarelli B, Fagnani C, Aloisi F.
    J Neuroinflammation; 2018 Jan 16; 15(1):18. PubMed ID: 29338732
    [Abstract] [Full Text] [Related]

  • 29. An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs.
    Gottschalk S, Ng CY, Perez M, Smith CA, Sample C, Brenner MK, Heslop HE, Rooney CM.
    Blood; 2001 Feb 15; 97(4):835-43. PubMed ID: 11159505
    [Abstract] [Full Text] [Related]

  • 30. Epstein-Barr virus-specific adoptive immunotherapy: a new horizon for multiple sclerosis treatment?
    Pender MP, Khanna R.
    Immunotherapy; 2014 Feb 15; 6(6):659-61. PubMed ID: 25186599
    [No Abstract] [Full Text] [Related]

  • 31. Increased T-cell responses to Epstein-Barr virus with high viral load in patients with Epstein-Barr virus-positive diffuse large B-cell lymphoma.
    Morishima S, Nakamura S, Yamamoto K, Miyauchi H, Kagami Y, Kinoshita T, Onoda H, Yatabe Y, Ito M, Miyamura K, Nagai H, Moritani S, Sugiura I, Tsushita K, Mihara H, Ohbayashi K, Iba S, Emi N, Okamoto M, Iwata S, Kimura H, Kuzushima K, Morishima Y.
    Leuk Lymphoma; 2015 Apr 15; 56(4):1072-8. PubMed ID: 24975317
    [Abstract] [Full Text] [Related]

  • 32. CD8+ T cells retain protective functions despite sustained inhibitory receptor expression during Epstein-Barr virus infection in vivo.
    Chatterjee B, Deng Y, Holler A, Nunez N, Azzi T, Vanoaica LD, Müller A, Zdimerova H, Antsiferova O, Zbinden A, Capaul R, Dreyer JH, Nadal D, Becher B, Robinson MD, Stauss H, Münz C.
    PLoS Pathog; 2019 May 15; 15(5):e1007748. PubMed ID: 31145756
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI.
    Farrell RA, Antony D, Wall GR, Clark DA, Fisniku L, Swanton J, Khaleeli Z, Schmierer K, Miller DH, Giovannoni G.
    Neurology; 2009 Jul 07; 73(1):32-8. PubMed ID: 19458321
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Epstein-Barr virus-immortalized B lymphocytes exacerbate experimental autoimmune encephalomyelitis in xenograft mice.
    Polepole P, Bartenslager A, Liu Y, Petro TM, Fernando S, Zhang L.
    J Med Virol; 2021 Jun 07; 93(6):3813-3823. PubMed ID: 32543727
    [Abstract] [Full Text] [Related]

  • 37. High-throughput sequencing of TCR repertoires in multiple sclerosis reveals intrathecal enrichment of EBV-reactive CD8+ T cells.
    Lossius A, Johansen JN, Vartdal F, Robins H, Jūratė Šaltytė B, Holmøy T, Olweus J.
    Eur J Immunol; 2014 Nov 07; 44(11):3439-52. PubMed ID: 25103993
    [Abstract] [Full Text] [Related]

  • 38. Adoptive immunotherapy for Epstein-Barr virus-associated lymphoproliferative disorders complicating marrow allografts.
    O'Reilly RJ, Small TN, Papadopoulos E, Lucas K, Lacerda J, Koulova L.
    Springer Semin Immunopathol; 1998 Nov 07; 20(3-4):455-91. PubMed ID: 9870257
    [No Abstract] [Full Text] [Related]

  • 39. Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection.
    Savoldo B, Huls MH, Liu Z, Okamura T, Volk HD, Reinke P, Sabat R, Babel N, Jones JF, Webster-Cyriaque J, Gee AP, Brenner MK, Heslop HE, Rooney CM.
    Blood; 2002 Dec 01; 100(12):4059-66. PubMed ID: 12393655
    [Abstract] [Full Text] [Related]

  • 40. Targeting Epstein-Barr virus in multiple sclerosis: when and how?
    Giovannoni G.
    Curr Opin Neurol; 2024 Jun 01; 37(3):228-236. PubMed ID: 38511407
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.